Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) Growing Patent Portfolio Enables Commercialization, Defense of DehydraTECH
LXRP recently received a new U.S. patent allowance for ‘composition of matter’ related to its DehydraTECH™ platform’s delivery of cannabinoids; based on past experience, company expects formal granting of patent within 100 days Company filed new U.S. patent application for use of DehydraTECH to improve the speed of absorption of active pharmaceutical ingredients through the skin; compared to other commercial formulations, LXRP product exhibited up to a 225 percent increase in permeability LXRP gets primary revenue through third party licensing fees related to its proprietary and patented intellectual property; goal is to partner with leading firms globally to deliver best-in-class…